61301-33-5
61301-33-5 结构式
基本信息
五味子丙素对照品,
五味子丙素(标准品)
五味子丙素(五味子素C)
SCHISANDRIN C 五味子丙素
SCHISANDRIN C 五味子丙素 标准品
,8-dimethyl-
SCHIZANDRIN C
(S)-(-)-Schisandrin C
WUWEIZISU C USP/EP/BP
Schisandrin C >=98% (HPLC)
Schisandrin C (Schizandrin-C
Schisandrin C (S)-(-)-Schisandrin C
cycloocta(1,2-f:3,4-f’)bis(1,3)benzodioxole6,7,8,9-tetrahydro-1,13-dimethoxy-7
(6R,7S,13aS)-5,6,7,8-Tetrahydro-13,14-dimethoxy-6,7-dimethylcycloocta[1,2-f:3,4-f']bis[1,3]benzodioxole
物理化学性质
常见问题列表
Schisandrin C (25-100 μM; 48 hours) down-regulates expression levels of Bcl-2, Bcl-xL and a concomitant degradation of poly(ADP-ribose) polymerase (PARP). It also activates caspase-3 and -9 in U937 cells.Schisandrin C (25-100 μM; 48 hours) induces apoptosis in a dose-dependent manner. And the fragmentation of genomic DNA is also increased in U937 cells.Schisandrin C (25-100 μM; 72 hours) induces G1 arrest, it down-regulates cyclin D1, cyclin E, cyclin-dependent kinase (Cdk) 4 and E2Fs expression, and also exhibits inhibition of pRB, and up-regulation of the Cdk inhibitor p21(WAF1/CIP1).
Western Blot Analysis
| Cell Line: | U937 cells |
| Concentration: | 25 μM,50 μM,100 μM |
| Incubation Time: | 48 hours |
| Result: | Decreased the expression of apoptosis related proteins. |
Apoptosis Analysis
| Cell Line: | U937 cells |
| Concentration: | 25 μM,50 μM,100 μM |
| Incubation Time: | 48 hours |
| Result: | Induced cell apoptosis. |
Cell Cycle Analysis
| Cell Line: | U937 cells |
| Concentration: | 25 μM,50 μM,100 μM |
| Incubation Time: | 48 hours |
| Result: | Induced growth inhibition and G1 arrest of U937 cells. |
Schisandrin C (lateral ventricle injection (i.c.v.); 15-150 μg/kg; 5 days) reduces Aβ1-42-induced memory deficits in the Y-maze test. Neurons in the hippocampus of SCH-C (15 μg/kg)-treated group returned to normal level, and and SCH-C group (150 μg/kg) has slight neuroprotective effects Aβ1-42-induced group. SCH-C (15 μg/kg) recoveres the activities of SOD and GSHPx and the ratios of GSH, decreases the levels of ChEtotal in the brain of the Aβ1–42-induced amnesic mice simultaneously.
| Animal Model: | Aβ1-42-induced Alzheimer’s disease mice |
| Dosage: | 15-150 μg/kg |
| Administration: | Lateral ventricle injection (i.c.v.); 15-150 μg/kg; 5 days |
| Result: | Exhibited potent neuroprotective effects linking to anti-ChEtotal activities and anti-oxidative mechanisms in Aβ1-42-induced amnestic mice. |